Amgen on IRA’s drug price negotiations: ‘Material adverse effect’ on sales, business and operations

Biologic powerhouse Amgen is making clear that President Biden’s signature law authorizing Medicare drug price negotiations is going to have a negative impact on the company moving forward, although how negative remains unknown. “The IRA’s drug pricing controls and Medicare redesign is likely to have a material adverse effect on…

...

Click to view original post